GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Semler Scientific Inc (NAS:SMLR) » Definitions » Debt-to-EBITDA

Semler Scientific (Semler Scientific) Debt-to-EBITDA : 0.01 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Semler Scientific Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Semler Scientific's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.09 Mil. Semler Scientific's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.05 Mil. Semler Scientific's annualized EBITDA for the quarter that ended in Mar. 2024 was $28.61 Mil. Semler Scientific's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Semler Scientific's Debt-to-EBITDA or its related term are showing as below:

SMLR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.12   Med: -0.24   Max: 0.02
Current: 0.01

During the past 13 years, the highest Debt-to-EBITDA Ratio of Semler Scientific was 0.02. The lowest was -6.12. And the median was -0.24.

SMLR's Debt-to-EBITDA is ranked better than
99.77% of 434 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs SMLR: 0.01

Semler Scientific Debt-to-EBITDA Historical Data

The historical data trend for Semler Scientific's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Semler Scientific Debt-to-EBITDA Chart

Semler Scientific Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.02 0.01 0.01

Semler Scientific Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Competitive Comparison of Semler Scientific's Debt-to-EBITDA

For the Medical Devices subindustry, Semler Scientific's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Semler Scientific's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Semler Scientific's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Semler Scientific's Debt-to-EBITDA falls into.



Semler Scientific Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Semler Scientific's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.09 + 0.07) / 23.589
=0.01

Semler Scientific's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.091 + 0.047) / 28.608
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Semler Scientific  (NAS:SMLR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Semler Scientific Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Semler Scientific's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Semler Scientific (Semler Scientific) Business Description

Traded in Other Exchanges
Address
2340-2348 Walsh Avenue, Suite 2344, Santa Clara, CA, USA, 95051
Semler Scientific Inc is a US-based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test.
Executives
Eric Semler director 4625 FIELDSTON ROAD, BRONX NY 10471
Renae Cormier officer: Chief Financial Officer C/O SEMLER SCIENTIFIC, INC., 2340-2348 WALSH AVE, SUITE 2344, SANTA CLARA CA 95051
Douglas Murphy-chutorian director, 10 percent owner, officer: Chief Executive Officer C/O SEMLER SCIENTIFIC, INC., 911 BERN COURT, SUITE 110, SAN JOSE CA 95112
Wayne T Pan director 2330 NW EVERETT STREET, PORTLAND OR 97210
William H.c. Chang & Diana Shon Chang Ttee Chang Family Trust U/a Dtd 10/23/2006 10 percent owner C/O SEMLER SCIENTIFIC, INC., 911 BERN CT., SAN JOSE CA 95112
Chang 2020 Delaware Lp 10 percent owner C/O SEMLER SCIENTIFIC, INC., 2340-2348 WALSH AVENUE, SUITE 2344, SANTA CLARA CA 95051
Arthur N Leibowitz director C/O I-TRAX INC, ONE LOGAN SQUARE STE 2615, PHILADELPHIA PA 19103
Chang 2020 Gp Llc 10 percent owner C/O SEMLER SCIENTIFIC, INC., 2340-2348 WALSH AVENUE, STE. 2344, SANTA CLARA CA 95051
Cindy Moon director C/O SEMLER SCIENTIFIC, INC., 911 BERN COURT, SAN JOSE CA 95112
Daniel S Messina director C/O SEMLER SCIENTIFIC, INC., 911 BERN COURT, STE. 110, SAN JOSE Z4 95112
Daniel E Conger officer: Vice President, Finance C/O SEMLER SCIENTIFIC, INC., 911 BERN COURT, SUITE 110, SAN JOSE CA 95112
William H Chang 10 percent owner C/O SEMLER SCIENTIFIC, INC., 911 BERN COURT, SUITE 110, SAN JOSE CA 95112
Diana Shon Chang 10 percent owner 1301 SHOREWAY RD., SUITE 150, BELMONT CA 94002
Andrew B. Weinstein officer: Senior VP, Finance and Acct. C/O SEMLER SCIENTIFIC, INC., 911 BERN COURT, SUITE 110, SAN JOSE CA 95112
Herbert J Semler director, 10 percent owner C/O SEMLER SCIENTIFIC, INC., 2330 NW EVERETT ST., PORTLAND OR 97210